"It was difficult to offer same day results": evaluation of community-based point-of-care testing for sexually transmitted infections among youth using the GeneXpert platform in Zimbabwe.
Africa
Community-based settings
Gonorrhoea
Point-of-care tests
Sexually transmitted infections
Youth
chlamydia
Journal
BMC health services research
ISSN: 1472-6963
Titre abrégé: BMC Health Serv Res
Pays: England
ID NLM: 101088677
Informations de publication
Date de publication:
10 Feb 2022
10 Feb 2022
Historique:
received:
02
09
2021
accepted:
27
01
2022
entrez:
11
2
2022
pubmed:
12
2
2022
medline:
15
2
2022
Statut:
epublish
Résumé
Point-of-care testing for sexually transmitted infections (STIs) may improve diagnosis and treatment of STIs in low- and middle-income counties. We explored the facilitators and barriers to point-of-care testing for Chlamydia trachomatis (CT) and Neisseria gonorrhoea (NG) for youth in community-based settings in Zimbabwe. This study was nested within a cluster randomised trial of community-based delivery of integrated HIV and sexual and reproductive health services for youth aged 16 to 24 years. On-site CT/NG testing on urine samples using the Xpert® CT/NG test was piloted in four intervention clusters, with testing performed by service providers. On-site testing was defined as sample processing on the same day and site as sample collection. Outcomes included proportion of tests processed on-site, time between sample collection and collection of results, and proportion of clients receiving treatment. In-depth interviews were conducted with nine service providers and three staff members providing study co-ordination or laboratory support to explore facilitators and barriers to providing on-site CT/NG testing. Of 847 Xpert tests, 296 (35.0%) were performed on-site. Of these, 61 (20.6%) were positive for CT/NG; one (1.6%) received same day aetiological treatment; 33 (54.1%) presented later for treatment; and 5 (8.2%) were treated as a part of syndromic management. There was no difference in the proportion of clients who were treated whether their sample was processed on or off-site (64% (39/61) vs 60% (66/110); p = 0.61). The median (IQR) number of days between sample collection and collection of positive results was 14 (7-35) and 14 (7-52.5) for samples processed on and off-site, respectively, The interviews revealed four themes related to the provision of on-site testing associated with the i) diagnostic device ii) environment, iii) provider, and iv) clients. Some of the specific barriers identified included insufficient testing capacity, inadequate space, as well as reluctance of clients to wait for their results. In addition to research to optimise the implementation of point-of-care tests for STIs in resource-limited settings, the development of new platforms to reduce analytic time will be necessary to scale up STI testing and reduce the attrition between testing and treatment. Registered in clinical trials.gov ( NCT03719521 ).
Sections du résumé
BACKGROUND
BACKGROUND
Point-of-care testing for sexually transmitted infections (STIs) may improve diagnosis and treatment of STIs in low- and middle-income counties. We explored the facilitators and barriers to point-of-care testing for Chlamydia trachomatis (CT) and Neisseria gonorrhoea (NG) for youth in community-based settings in Zimbabwe.
METHODS
METHODS
This study was nested within a cluster randomised trial of community-based delivery of integrated HIV and sexual and reproductive health services for youth aged 16 to 24 years. On-site CT/NG testing on urine samples using the Xpert® CT/NG test was piloted in four intervention clusters, with testing performed by service providers. On-site testing was defined as sample processing on the same day and site as sample collection. Outcomes included proportion of tests processed on-site, time between sample collection and collection of results, and proportion of clients receiving treatment. In-depth interviews were conducted with nine service providers and three staff members providing study co-ordination or laboratory support to explore facilitators and barriers to providing on-site CT/NG testing.
RESULTS
RESULTS
Of 847 Xpert tests, 296 (35.0%) were performed on-site. Of these, 61 (20.6%) were positive for CT/NG; one (1.6%) received same day aetiological treatment; 33 (54.1%) presented later for treatment; and 5 (8.2%) were treated as a part of syndromic management. There was no difference in the proportion of clients who were treated whether their sample was processed on or off-site (64% (39/61) vs 60% (66/110); p = 0.61). The median (IQR) number of days between sample collection and collection of positive results was 14 (7-35) and 14 (7-52.5) for samples processed on and off-site, respectively, The interviews revealed four themes related to the provision of on-site testing associated with the i) diagnostic device ii) environment, iii) provider, and iv) clients. Some of the specific barriers identified included insufficient testing capacity, inadequate space, as well as reluctance of clients to wait for their results.
CONCLUSIONS
CONCLUSIONS
In addition to research to optimise the implementation of point-of-care tests for STIs in resource-limited settings, the development of new platforms to reduce analytic time will be necessary to scale up STI testing and reduce the attrition between testing and treatment.
TRIAL REGISTRATION
BACKGROUND
Registered in clinical trials.gov ( NCT03719521 ).
Identifiants
pubmed: 35144602
doi: 10.1186/s12913-022-07557-7
pii: 10.1186/s12913-022-07557-7
pmc: PMC8830017
doi:
Banques de données
ClinicalTrials.gov
['NCT03719521']
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
171Subventions
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 206316/Z/17/Z
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/T040327/1
Pays : United Kingdom
Informations de copyright
© 2022. The Author(s).
Références
PLoS One. 2020 Mar 19;15(3):e0230604
pubmed: 32191768
AIDS Behav. 2019 Apr;23(4):813-819
pubmed: 30506350
Infect Dis Obstet Gynecol. 2018 May 9;2018:3946862
pubmed: 29861622
Sex Transm Dis. 2007 Jul;34(7):421-8
pubmed: 17091118
Int J Qual Health Care. 2007 Dec;19(6):349-57
pubmed: 17872937
BMC Infect Dis. 2016 Jun 06;16:250
pubmed: 27268218
Sex Transm Dis. 2009 Nov;36(11):714-20
pubmed: 19773681
Sex Transm Dis. 2020 Jan;47(1):67-69
pubmed: 31856075
Clin Microbiol Infect. 2019 May;25(5):623-627
pubmed: 30107282
BMC Health Serv Res. 2015 Nov 05;15:495
pubmed: 26541668
BMC Infect Dis. 2019 Feb 4;19(1):110
pubmed: 30717693
BMC Infect Dis. 2021 Dec 8;21(1):1234
pubmed: 34879820
BMC Health Serv Res. 2017 Aug 14;17(1):556
pubmed: 28807019
AIDS. 2021 Oct 1;35(12):2039-2041
pubmed: 34471072
Int J STD AIDS. 2020 Mar;31(3):221-229
pubmed: 31996095
Biomed Res Int. 2020 Oct 8;2020:2892734
pubmed: 33102576
Gates Open Res. 2018 Jul 25;2:35
pubmed: 30234198
Lancet Child Adolesc Health. 2021 Feb;5(2):122-132
pubmed: 33417838
Int J Gynaecol Obstet. 2015 Jun;130 Suppl 1:S15-21
pubmed: 26001704
Bull World Health Organ. 2019 Aug 1;97(8):548-562P
pubmed: 31384073
J Adolesc Health. 2016 Jul;59(1):7-16
pubmed: 27338664
PLoS One. 2015 Apr 13;10(4):e0124161
pubmed: 25875336
Lancet Infect Dis. 2019 Jun;19(6):658-669
pubmed: 31031172
BMJ Open. 2015 Sep 18;5(9):e008552
pubmed: 26384725
Sex Transm Infect. 2006 Dec;82 Suppl 5:v1-6
pubmed: 17151023
Sex Transm Infect. 2007 Dec;83(7):552-7
pubmed: 17901084
Curr Opin HIV AIDS. 2018 May;13(3):257-264
pubmed: 29401121
Sex Transm Infect. 2020 Aug;96(5):342-347
pubmed: 32241905
PLoS Med. 2018 Feb 27;15(2):e1002511
pubmed: 29485986
PLoS One. 2018 Apr 24;13(4):e0196209
pubmed: 29689080
Prev Med. 2003 Apr;36(4):502-9
pubmed: 12649059
Biomed Res Int. 2016;2016:1251238
pubmed: 27119076
PLoS Med. 2012;9(6):e1001233
pubmed: 22719229
Int J STD AIDS. 2014 Apr;25(5):325-31
pubmed: 24108451
BMC Health Serv Res. 2018 May 11;18(1):363
pubmed: 29751798
Sex Transm Infect. 1999 Feb;75(1):3-17
pubmed: 10448335